Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orforglipron in Peripheral Artery Disease
NCT07223593Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2025
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial in Peripheral Arterial Disease (PAD) comparing Orforglipron with Placebo (2 arms). Primary endpoint: Maximum Walking Distance at 52 weeks. Started Oct 2025; status: recruiting.
02
Drugs
orforglipron
03
Conditions
Peripheral Arterial Disease (PAD)
Beyond the preview
Go deeper on NCT07223593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07223593.